6. Patient has an AR-positive and PTEN-positive tumor as determined by using Clinical Laboratory Improvement Amendments (CLIA) compliant assays to identify AR-positive and PTEN-positive disease (AR positivity is defined as >/= 1% of nuclear staining, PTEN positivity is defined as >0% of nuclear staining).